Mobile App

Google Play Apple Store
Emerging Evidence in Myasthenia Gravis: Key Updates from AAN 2025*
AMA/ABS/ANCC/ACPE-Clinical Clip
In this Clinical Clip, Dr. Nicholas Silvestri provides a concise and clinically relevant summary of the most important emerging data presented at AAN 2025 that impact the management of generalized Myasthenia Gravis (gMG).

Topics covered include pivotal updates from recent clinical trials—such as MINT (inebilizumab), ADAPT NXT (efgartigimod), and MycarinG (rozanolixizumab)—highlighting the safety, efficacy, and practical implications of emerging therapies across diverse MG subtypes. The activity also explores trends in real-world treatment patterns, therapeutic inertia among neurologists, and new diagnostic approaches including advanced serologic testing and AI-supported electrophysiologic tools. With a focus on individualized care, this activity equips healthcare professionals with key insights to help integrate new therapies and diagnostic innovations into practice, ultimately supporting timely, targeted, and patient-centered management of MG.
Review the activity and claim AMA, ABS, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.





 
Nicholas Silvestri, MD, FAAN Nicholas Silvestri, MD, FAAN
Professor of Neurology, Associate Dean for Student and Academic Affairs
Department of Neurology
Jacobs School of Medicine & Biomedical Sciences

* This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of the American Academy of Neurology (AAN) 2025 Annual Meeting.
20
Supported by an independent educational grants from UCB Inc.

Launch Date: April 10, 2025
Release Date: April 10, 2025
Expiration Date: March 31, 2026

Mini Module
7908
AANConf_CC(1730x162).gif
True
Neurology

CookieConsent

Change Settings